2-(2-氨基-1H-苯并咪唑-1-基)-8-甲氧基-N-(苯甲基)-4-喹唑啉胺 | 1346527-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-(2-氨基-1H-苯并咪唑-1-基)-8-甲氧基-N-(苯甲基)-4-喹唑啉胺
• 英文名称: 2-(2-amino-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine
• 英文别名: 2-(2-aminobenzimidazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine
• CAS: 1346527-98-7
• 化学式: C₂₃H₂₀N₆O
• 分子量: 396.4
• InChiKey: NHAMBLRUUJAFOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  90.9
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• WGK Germany：
  3
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

文献信息

• FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX
  申请人：Cleave Biosciences, Inc.

  公开号：US20170258795A1

  公开（公告）日：2017-09-14

  Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

  本发明公开了一种融合嘧啶化合物，其具有饱和，不饱和或芳香性A环融合到嘧啶环上，并在嘧啶环的2位位置具有复杂的取代基和取代胺在嘧啶环的4位位置，以及可选的脂肪烷基，功能性和/或芳香基组分取代在嘧啶环和A环的其他位置。这些化合物是AAA蛋白酶复合物的抑制剂，包含p97，并且是用于治疗与p97生物活性相关的疾病的有效药物，例如癌症。
• Fused pyrimidines as inhibitors of P97 complex
  申请人：Cleave Biosciences, Inc.

  公开号：US10010554B2

  公开（公告）日：2018-07-03

  Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

  本发明公开了具有与嘧啶环融合的饱和、不饱和或芳香 A 环的融合嘧啶化合物，该化合物在嘧啶环的 2 位具有复合取代基，在 4 位具有取代胺，并在嘧啶环和 A 环的其他位置具有任选取代的脂肪族、官能团和/或芳香族成分。这些化合物是含有 p97 的 AAA 蛋白酶体复合物的抑制剂，是治疗与 p97 生物活性有关的疾病（如癌症）的有效药物。
• FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
  申请人：Cleave Biosciences, Inc.

  公开号：EP2875018B1

  公开（公告）日：2018-02-14
• COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION
  申请人：The Johns Hopkins University

  公开号：EP3515448A1

  公开（公告）日：2019-07-31
• METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE
  申请人：Deshaies Raymond J.

  公开号：US20110288082A1

  公开（公告）日：2011-11-24

  Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate. Methods and compositions are disclosed for inhibiting p97 ATPase and the degradation of a p97-dependent UPS substrate, and for identifying inhibitors thereof